BioSpace News Archive

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an agreement with LabCorp® (NYSE: LH) to extend their current QIAGEN Clinical Insights (QCI) license with QIAGEN’s Human Gene Mutation Database (HGMD) of human genetic variants, the world’s largest database of inherited disease mutations.

Here are some holiday tips to support your efforts for health and safety during the season.

Celgene Corporation announced that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company, Bristol-Myers Squibb and Celgene plan to transfer the listing of Celgene’s contingent value rights that are related to Celgene’s ABRAXANE® product from the NASDAQ Global Market to the New York Stock Exchange

European Patent EP3004337 Upheld by the EPO in Favor of Cellectis, Refers to the Method of Preparing T-Cells for Immunotherapy Using the RNA-Guided CRISPR-Cas9 Nuclease System

Phio Pharmaceuticals Corp. announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.10 per share.

Therapix Biosciences Ltd. announced that it received a written Notice of Delisting from the Listing Qualifications Department of The Nasdaq Capital Market (“Nasdaq”).

CRISPR Therapeutics announced the pricing of an underwritten public offering of 4,250,000 common shares at a public offering price of $64.50 per share.

Bayer announced it has joined Know Diabetes by Heart™, a joint initiative of the American Heart Association and the American Diabetes Association, as a national sponsor.

The Doctors Company announced the promotion of longtime company executive Marco Vanderlaan to chief financial officer and chief risk officer.

Mednet, a provider of eClinical solutions for the global life sciences community and Assign DMB, a contract research organization with deep expertise in data management and biostatistics, announced they extended their four-year relationship.